Dynamics of sequencing of cyclin-dependent kinase inhibitors and cost expenditure analysis in the management of metastatic hormone-receptor positive, human epidermal growth factor 2-negative advancedbreast cancer

Abstract

Palbociclib, ribociclib, and abemaciclib are now approved as first-line therapy for HR+ advanced breast cancer in combination with aromatase inhibitors (AIs) in postmenopausal women. [7] The subsequent lines could never be evidence based after that as there is no data on how AI + CDK4/6 inhibition will work after exposure to fulvestrant. [...]it is likely that the recommendations of use in first line will remain the same in future. {Figure 1}{Figure 2} In palliative setting, treatment is continued indefinitely till progression. [...]if two ways of sequencing therapies generate equivalent overall outcomes, a strategy which uses any expensive drug for a shorter duration should be the clear winner.